US FDA has approved Tykerb (lapatinib, manufactured by GlaxoSmithKline) in combination therapy with Xeloda (capectabine, manufactured by Roche) for treating HER2 positive, advanced metastatic breast cancer in patients who have previously been treated with other cancer drugs including anthracyclines, taxanes, and trastuzumab (Herceptin, manufactured by Genentech). Tykerb is a dual-receptor tyrosine kinase inhibitor that slows down cancer cell growth by interfering with growth signals. This drug is considered a new molecular entity in cancer treatment. Patients who received the Tykerb-Xeloda combination treatment had a longer time to tumor progression than patients who received only Xeloda. Survival rates data are still not mature (too early to tell). Common side effects included diarrhea, nausea, vomiting, rash, and hand-foot syndrome. Source: FDA website.
Latest Tips RSS
-
TargetingTumors.com
-
TargetingTumors.com
GlaxoSmithKline is the manufacturer of Tykerb (lapatinib), a tyrosine kinase inhibitor that targets HER2 (ErbB2) to prevent cell growth and proliferation. Tykerb is still an investigational drug and has not been approved by the FDA. The manufacturer has announced that the New England Journal of Medicine has published a landmark phase III trial results of Tykerb and Xeloda in HER2 positive advanced breast cancer that had already been treated with therapies including (More …)